What is the Tafluprost?

Tafluprost is , while it's Molecular Formula is C 25 H 34 F 2 O 5 . Tafluprost is a novel prostanoid used in the treatment of glaucoma and is the first prostanoid to be released in a preservative free-formula.

What is the CAS number for Tafluprost?

The CAS number of Tafluprost is 209860-87-7.

What is Tafluprost (209860-87-7) used for?

Glaucoma is second only to cataracts as a causative factor of blindness.By 2010, it is estimated that approximately 60 million people worldwidewill be afflicted by glaucoma, so effective treatments should garner a large market. PG analogs have been widely used for lowering IOP by increasing uveoscleral outflow through agonism of the prostanoid FPreceptor, and currently marketed versions include latanoprost, unoprostone isopropyl ester, bimatoprost, and travoprost. Compared to the carboxylic acid of latanaprost(Ki=4.7 nM), the carboxylic acid of tafluprost displayed a 10-fold greateraffinity for the prostanoid FP receptor (Ki=0.4 nM). The synthesis oftafluprost begins with a Wittig condensation of the protected bicycliclactone carbaldehyde with a dimethyl phosphonate ketone derivative.Compared to the carboxylic acid of latanaprost (Ki 4.7 nM), the carboxylic acid of tafluprost displayed a 10-fold greater affinity for the prostanoid FP receptor (Ki 0.4 nM). The synthesis of tafluprost begins with a Wittig condensation of the protected bicyclic lactone carbaldehyde with a dimethyl phosphonate ketone derivative. The bottom appendage is then completed by the fluorination of the ketone with morpholino-sulfur trifluoride. Hydrolysis of the benzoate ester protecting group liberates the hydroxy group, and reduction of the lactone is accomplished with aluminum hydride to generate the lactol. Condensation of this intermediate with the phosphonium salt of the acid side chain generates the free acid, or active ingredient, which is subsequently esterified with 2-iodopropane in the presence of DBU..InChI:InChI=1/C25H34F2O5/c1-18(2)32-24(30)13-9-4-3-8-12-20-21(23(29)16-22(20)28)14-15-25(26,27)17-31-19-10-6-5-7-11-19/h3,5-8,10-11,14-15,18,20-23,28-29H,4,9,12-13,16-17H2,1-2H3/b8-3+,15-14+

Product Class

209860-87-7

Product Name：Tafluprost
Molecular Formula：C₂₅H₃₄F₂O₅
Purity：99%
Molecular Weight：452.539

Inquiry

Product Details:

CasNo： 209860-87-7

Molecular Formula： C₂₅H₃₄F₂O₅

Buy High Purity 99% High Grade Tafluprost 209860-87-7 Safe Delivery

Molecular Formula:C₂₅H₃₄F₂O₅
Molecular Weight:452.539
Vapor Pressure:4.62E-13mmHg at 25°C
Refractive Index:1.548
Boiling Point:552.9ºC at 760mmHg
PKA:14.48±0.70(Predicted)
Flash Point:288.2°C
PSA：75.99000
Density:1.186 g/cm³
LogP:4.68300

Tafluprost(Cas 209860-87-7) Usage

Description	Tafluprost is a prostaglandin analogue medication used in ophthalmology to lower intraocular pressure (IOP) in patients with glaucoma and ocular hypertension. It belongs to the class of medications called prostaglandin analogs, which work by reducing pressure within the eye.
Originator	Santen/Asahi Glass (Japan)
Uses	Preclinical studies in animals demonstrated that tafluprost has potent IOP-lowering effects at a concentration of 0.005%. Pharmacokinetic studies showed rapid absorption into ocular tissues and systemic circulation. Phase I and II clinical trials indicated that tafluprost has a stronger IOP-lowering effect compared to other prostaglandin analogues, with fewer and milder local side effects.
Definition	ChEBI: A prostaglandin Falpha that is prostaglandin F2alpha in which the carboxylic acid function has been converted to the corresponding isopropyl ester and the 3-hydroxy-1-octenyl side- hain is substituted by 3,3-difluoro-4-phenoxybut-1-enyl. Used for treatment of elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension.
Brand name	Taflotan
FDA Approval	Tafluprost, marketed under the brand name Zioptan, was approved by the FDA on February 10, 2012, for the treatment of glaucoma and ocular hypertension. It is available as an ophthalmic solution.

InChI:InChI=1/C25H34F2O5/c1-18(2)32-24(30)13-9-4-3-8-12-20-21(23(29)16-22(20)28)14-15-25(26,27)17-31-19-10-6-5-7-11-19/h3,5-8,10-11,14-15,18,20-23,28-29H,4,9,12-13,16-17H2,1-2H3/b8-3+,15-14+

209860-87-7 Relevant articles

Synthesis of the highly potent prostanoid FP receptor agonist, AFP-168: A novel 15-deoxy-15,15-difluoroprostaglandin F2α derivative

Matsumura, Yasushi,Mori, Nobuaki,Nakano, Takashi,Sasakura, Hideshi,Matsugi, Takeshi,Hara, Hideaki,Morizawa, Yoshitomi

, p. 1527 - 1529 (2004)

A novel 15-deoxy-15,15-difluoro-prostagl...

A Comparative, Placebo-Controlled Study of Prostanoid Fluoroprostaglandin-Receptor Agonists Tafluprost and Latanoprost in Healthy Males

Andrew Sutton, Anne Gilvarry, and Auli Ropo

Paragraph 0101-0103, (2021/05/29)

This was a phase I study in healthy males 18–45 years of age (N = 49). Participants were randomized to receive 1 of 4 eye drops: tafluprost 0.0025% or 0.005%, latanoprost 0.005%, or a placebo, administered once-daily for 7 days, with 1 drop per eye.

An Asymmetric Suzuki-Miyaura Approach to Prostaglandins: Synthesis of Tafluprost

Fletcher, Stephen P.,Goetzke, F. Wieland,Ku?era, Roman

Journal of Ocular Pharmacology and Therapeutics.Aug 2007.359-365.

We report the catalytic asymmetric synth...

Crystal form of metallic salt compound of Tafluprost acid and preparation method of crystal form

-

, (2019/04/27)

The invention relates to a crystal form ...

209860-87-7 Process route

: 75-30-9
2-iodo-propane

: 209860-88-8
AFP-172

: 209860-87-7
tafluprost

Conditions

Conditions	Yield
AFP-172; With 1,8-diazabicyclo[5.4.0]undec-7-ene; In acetone; at 0 ℃; Inert atmosphere; 2-iodo-propane; at 0 - 20 ℃; for 21h; Inert atmosphere;	83%
With 1,8-diazabicyclo[5.4.0]undec-7-ene; In acetone; at 5 - 30 ℃; Inert atmosphere;	82%
With 1,8-diazabicyclo[5.4.0]undec-7-ene; In acetone; at 20 ℃; for 16h;
With 1,8-diazabicyclo[5.4.0]undec-7-ene; In acetone; at 20 ℃; for 16h;
With 1,8-diazabicyclo[5.4.0]undec-7-ene; In acetone; at 20 ℃;
With potassium carbonate; In N,N-dimethyl-formamide; at 80 ℃; for 2h; Inert atmosphere;	6.8 g
With potassium carbonate; In N,N-dimethyl-formamide; at 80 ℃; for 2h; Inert atmosphere;	6.8 g
With 1,8-diazabicyclo[5.4.0]undec-7-ene; In acetone; at 20 ℃; for 22h;	9 mg
With 1,8-diazabicyclo[5.4.0]undec-7-ene; In acetone; at 28 - 32 ℃; for 5h;	29.85 g

: (Z)-7-{(1R,2R,3R,5S)-3-[(tert-butyldimethylsilanyl)oxy]-2-((E)-3,3-difluoro-4-phenoxybut-1-en-1-yl)-5-hydroxy-cyclopentyl} hepta-5-enoic acid isopropyl ester

: 209860-87-7
tafluprost